Armotraz 1mg Tablet (Anastrozole)

Armotraz 1mg Tablet (anastrozole) is an anti-neoplastic medication that is used to treat hormone-positive breast cancer (HR+) in postmenopausal women. It is a part of hormone-based therapy that targets the specific estrogen hormone which is responsible for cancer cell growth and proliferation. Armotraz contains anastrozole, which belongs to the class of aromatase inhibitors. It blocks the specific aromatase enzyme involved in estrogen production. It lowers down the estrogen level in the postmenopausal women, reducing the estrogen-driven breast cancer.

The tablet is taken orally and exactly as prescribed by the doctor. The tablet must be swallowed whole with water and should not be crushed, chewed, or broken. It is usually taken with or without food. Anastrozole 1mg tablets are given once daily, and a doctor decides the dose and timings according to the patient's condition, combination therapy, clinical response, and stage of cancer. Patients are advised not to change the dosage because it can lead to severe side effects.

Common side effects include hot flashes, sweating, weakness, tiredness, headache, nausea, joint or muscle pain, stiffness, mood changes, and difficulty sleeping. A few patients can undergo severe side effects, including severe allergic reactions, significant liver problems, chest pain, or symptoms of heart disease. Most of the Anastrozole 1mg tablet side effects can resolve when the body adapts to the medicine. However, if any side effects persist, inform your doctor immediately.

The medicine should not be used during pregnancy because it may harm an unborn baby. Patients must list all medicines, supplements, and herbal products that they are taking. The Anastrozole 1mg tablet must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine's response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Hormone Receptor-Positive Breast Cancer

Armotraz 1mg Tablet (anastrozole) causes multiple side effects, from mild to extreme. Patients should seek immediate medical attention if they experience severe or worsening symptoms, especially the rare ones.

Common Side Effects of Armotraz 1mg Tablet
● Hot Flashes
● Nausea
● Joint Pain
● Bone Pain
● Diarrhea
● Weakness
● Vomiting
● Depression and Mood Changes
● High Cholesterol Level
● Rashes
● Vaginal dryness
● Vaginal bleeding
● Loss of Appetite

Rare Side Effects of Armotraz 1mg Tablet
● Severe Allergic Reaction
● Liver Problems (Jaundice, Dark Urine)
● Heart-Related Issues 

The typical dosage of Armotraz 1mg Tablet (anastrozole) is 1 tablet daily. The tablet needs to be swallowed whole. Avoid chewing, breaking, or crushing the tablet, as it may affect its efficacy. Dosage may vary based on the treatment stage and cancer stage as well as the patient's overall health. Consult your doctor for personalized dosage and guidance.

● Sanford, M., & Plosker, G. L. (2008). Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs, 68(9), 1319-1340.
● Jakesz, R., Greil, R., Gnant, M., Schmid, M., Kwasny, W., Kubista, E., ... & Samonigg, H. (2007). Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. Journal of the National Cancer Institute, 99(24), 1845-1853.
● Smith, I., Yardley, D., Burris, H. A., De Boer, R., Amadori, D., McIntyre, K., ... & O’Shaughnessy, J. (2017). Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor–positive, node-positive early breast cancer: Final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial. Journal of clinical oncology, 35(10), 1041-1048.
● Abubakar, M. B., Wei, K., & Gan, S. H. (2014). The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. Pharmacogenetics and Genomics, 24(12), 575-581.